Proactive London's Andrew Scott speaks to 's () chief financial officer Richard Barfield and head of clinical development Dr Gordana Tonkovic.
The firm's involved in a study at the Papa Giovanni XXIII Hospital in Bergamo, in Italy where the siltuximab antibody is being trialled in the treatment of patients with serious respiratory complications caused by COVID-19.
Ergomed's also had its results out this morning for 2019 which revealed £68.3mln of revenue for the twelve months ended 31 December, up 26.1%.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE